通过影响免疫细胞和免疫反应来调节过敏性喘
Zheng Jin1, Zhenhua Zhu2, Xiaopeng Jing1
1Department of Clinical Laboratory, Wuhan Fourth Hospital, Wuhan City, Hubei Province, China.
Biochemistry and biophysics reports
|September 2, 2025
概括
在过敏性喘中关键的过程, 影响免疫细胞功能和炎症. 针对无处不在的途径为治疗喘症状和改善患者的结果提供了有希望的新治疗策略.
科学领域:
- 免疫学
- 分子生物学
- 呼吸系统医学
背景情况:
- 过敏性喘的特征是呼吸道过度反应和重塑.
- 在过敏喘的发病过程中,后翻译性修饰具有重要作用.
- 这一过程影响了参与过敏反应的重要免疫细胞功能.
研究的目的:
- 审查在过敏性喘中调节免疫反应中的ubiquitination作用.
- 讨论泛素连接酶,基质和免疫细胞功能之间的相互作用.
- 探索喘治疗的治疗潜力.
主要方法:
- 关于无处不在和过敏喘的文献综述.
- 对 Th2 细胞分化和细胞因子产生影响的分析.
- 检查泛素修饰酶与免疫细胞信号之间的关系.
主要成果:
- 化对Th2细胞,B细胞和抗原呈现细胞的激活和功能产生关键影响.
- 特定的泛素连接酶及其基质参与调节喘中的关键炎症途径.
- 调节泛化通路会影响Th2细胞因子的产生和免疫细胞的信号传递.
结论:
- 对于开发新喘治疗来说, 了解无处不在在免疫反应中的作用至关重要.
- 针对无处不在的途径为改善过敏喘症状提供了一个有希望的策略.
- 对无处不在机制的进一步研究可以确定有效治疗喘的新治疗点.
相关概念视频
Asthma-II: Pathophysiology and Classification
2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K
Antiasthma Drugs: Leukotriene Modifiers
461
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
461
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
451
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
451
Asthma: Pathogenesis and Management
576
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
576
Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Allergic Reactions
28.5K
Overview
28.5K


